An Update on Xanomeline-trospium (Cobenfy) for Schizophrenia: Emerging Evidence and Clinical Implications
4 affiliations
- 1Department of Pharmacy, Duke Regional Hospital, Durham, NC, USA
- 2Department of Pharmacy, First Health Moore Regional Hospital, Pinehurst, NC, USA
- 3Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA
- 4Department of Pharmacy, Duke University Hospital, Durham, NC, USA
Abstract
Xanomeline-trospium (Cobenfy) is a novel treatment for schizophrenia that exerts its therapeutic benefit through muscarinic receptors without direct dopamine receptor effect. Xanomeline is a muscarinic M1- and M4-preferring receptor agonist, while trospium acts as a peripherally acting muscarinic antagonist that mitigates cholinergic adverse effects without crossing the blood–brain barrier. Since our initial publication in this journal reviewing data from the EMERGENT clinical trials, additional evidence has emerged that further characterizes the efficacy, safety, and clinical role of xanomeline-trospium in schizophrenia. This review provides an overview of recent evidence. Across pooled analyses of randomized trials, xanomeline-trospium demonstrated clinically meaningful improvements in positive, negative, cognitive, and agitation-related symptoms, with treatment effects observed as early as week 2 on some measures. Benefits were observed in patients with prominent negative symptoms, greater cognitive impairment, and higher levels of agitation at baseline. Long-term open-label studies demonstrated sustained improvement in symptoms and tolerability over 52 weeks among both previously treated and treatment-naïve patients, supporting findings from the 5-week EMERGENT trials. Improvements in functional impairment were also reported. Xanomeline-trospium was well tolerated, with gastrointestinal adverse effects occurring more frequently than placebo, while rates of extrapyramidal symptoms, clinically meaningful weight gain, and metabolic disturbances were low and comparable to or lower than placebo. Indirect comparisons to antipsychotics further suggested favorable benefit to risk profile. These findings provide continued support of xanomeline-trospium as an effective and well-tolerated treatment for schizophrenia. Future research is needed to assess the effectiveness of xanomeline-trospium across different stages of schizophrenia and through head-to-head trials.
Related
- The Interplay Between Pediatric Atopic Dermatitis and Neurodevelopmental Disorders: Emerging Evidence, Mechanistic Insights, and Clinical Implications
- Mitochondrial Dysfunction in Diabetic Neuropathy: An Evidence Map of Molecular Mechanisms, Translational Biomarkers, and Emerging Implications for Oral Neuropathy-A Scoping Review.
- The role of plasma oxytocin in early-onset schizophrenia: implications for disease severity and early intervention.
- GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers
- Blockade of Kv3.1 by MK-801, a PCP-Derivative NMDA Receptor Inhibitor: Implications for Models of Schizophrenia
BibTeX
@article{rayfield2026update,
title = {{An Update on Xanomeline-trospium (Cobenfy) for Schizophrenia: Emerging Evidence and Clinical Implications}},
author = {Amber Rayfield and Jessica Dorrough and Amanda Herman and Sydney Hege and Andrew Muzyk},
journal = {Clinical Psychopharmacology and Neuroscience},
year = {2026},
month = sep,
doi = {10.9758/cpn.26.1406},
url = {https://doi.org/10.9758/cpn.26.1406},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - An Update on Xanomeline-trospium (Cobenfy) for Schizophrenia: Emerging Evidence and Clinical Implications
AU - Amber Rayfield
AU - Jessica Dorrough
AU - Amanda Herman
AU - Sydney Hege
AU - Andrew Muzyk
PY - 2026
DA - 2026/09/02
JO - Clinical Psychopharmacology and Neuroscience
DO - 10.9758/cpn.26.1406
UR - https://doi.org/10.9758/cpn.26.1406
AB - Xanomeline-trospium (Cobenfy) is a novel treatment for schizophrenia that exerts its therapeutic benefit through muscarinic receptors without direct dopamine receptor effect. Xanomeline is a muscarinic M1- and M4-preferring receptor agonist, while trospium acts as a peripherally acting muscarinic antagonist that mitigates cholinergic adverse effects without crossing the blood–brain barrier. Since our initial publication in this journal reviewing data from the EMERGENT clinical trials, additional evidence has emerged that further characterizes the efficacy, safety, and clinical role of xanomeline-trospium in schizophrenia. This review provides an overview of recent evidence. Across pooled analyses of randomized trials, xanomeline-trospium demonstrated clinically meaningful improvements in positive, negative, cognitive, and agitation-related symptoms, with treatment effects observed as early as week 2 on some measures. Benefits were observed in patients with prominent negative symptoms, greater cognitive impairment, and higher levels of agitation at baseline. Long-term open-label studies demonstrated sustained improvement in symptoms and tolerability over 52 weeks among both previously treated and treatment-naïve patients, supporting findings from the 5-week EMERGENT trials. Improvements in functional impairment were also reported. Xanomeline-trospium was well tolerated, with gastrointestinal adverse effects occurring more frequently than placebo, while rates of extrapyramidal symptoms, clinically meaningful weight gain, and metabolic disturbances were low and comparable to or lower than placebo. Indirect comparisons to antipsychotics further suggested favorable benefit to risk profile. These findings provide continued support of xanomeline-trospium as an effective and well-tolerated treatment for schizophrenia. Future research is needed to assess the effectiveness of xanomeline-trospium across different stages of schizophrenia and through head-to-head trials.
SN - 1738-1088
SN - 2093-4327
ER -